MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$5,244K
EPS
-$0.34
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development
1,819
114
5,944*
570
General and administrative
3,431
5,425
3,286*
3,027
Acquired in-process research and development
0
22,180
-
-
Loss from operations
-5,250
-27,719
-9,230*
-3,597
Interest expense
0
0
138*
0
Interest income and other income (expense), net
6
23
178*
86
Total other income (expense), net
6
23
40*
86
Provision for income taxes
0
0
0*
0
Net loss
-5,244
-27,696
-9,190
-3,511
Basic EPS
-0.34
-2.53
-2.185
-0.79
Diluted EPS
-0.34
-2.53
-2.185
-0.79
Basic Average Shares
15,223,972
10,931,593
4,206,132
4,440,111
Diluted Average Shares
15,223,972
10,931,593
4,206,132
4,440,111
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Interest income and other
income (expense), net
$6K
(-95.77%↓ Y/Y)
Net loss
-$5,244K
(33.37%↑ Y/Y)
Total other income
(expense), net
$6K
(-93.75%↓ Y/Y)
Loss from operations
-$5,250K
(34.09%↑ Y/Y)
General and
administrative
$3,431K
(-16.21%↓ Y/Y)
Research and development
$1,819K
(-53.01%↓ Y/Y)
Buy us a coffee
Tempest Therapeutics, Inc. (TPST)
Tempest Therapeutics, Inc. (TPST)